Group 1 - Klotho Neurosciences, Inc. raised over $11 million through the exercise of existing warrants by investors [1][6] - The company believes it now exceeds Nasdaq's stockholders' equity requirements outlined in its compliance plan [1][6] - Klotho utilized $3.1 million of the raised funds to extinguish all outstanding debt, resulting in a debt-free balance sheet [2][6] Group 2 - Klotho Neurosciences focuses on developing innovative, disease-modifying cell and gene therapies targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [3] - The company's portfolio includes proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays [3] - Klotho is managed by a team experienced in biopharmaceutical product development and commercialization [3]
KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT